Thoughts on Bayer's 2021 Capital Markets Day
Here is a brief preview of this blast: Earlier this week, Bayer hosted its 2021 Capital Markets Day and provided a company-wide update (view transforming pharma slides; view pharma R&D slides). Bayer's President of Pharmaceuticals, Stefan Oelrich, provided a strategic update on the business, insights into the ongoing transformation, and the path for creating value through 2024. Unsurprisingly, finerenone and Verquvo (vericiguat) were highlighted as key parts of the company's return-to-growth strategy in the context of the impending Xarelto and Eylea LOEs. Below, FENIX provides highlights and insights from the Bayer 2021 CMD event related to CVRM.